HK1167108A1 - 用於降低甲狀旁腺激素水平的治療劑 - Google Patents

用於降低甲狀旁腺激素水平的治療劑

Info

Publication number
HK1167108A1
HK1167108A1 HK12107946.6A HK12107946A HK1167108A1 HK 1167108 A1 HK1167108 A1 HK 1167108A1 HK 12107946 A HK12107946 A HK 12107946A HK 1167108 A1 HK1167108 A1 HK 1167108A1
Authority
HK
Hong Kong
Prior art keywords
therapeutic agents
parathyroid hormone
hormone levels
reducing parathyroid
reducing
Prior art date
Application number
HK12107946.6A
Other languages
English (en)
Inventor
Felix Karim
Amos Baruch
Derek Maclean
Kanad Das
Qun Yin
Original Assignee
Kai Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43527590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1167108(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kai Pharmaceuticals Inc filed Critical Kai Pharmaceuticals Inc
Publication of HK1167108A1 publication Critical patent/HK1167108A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
HK12107946.6A 2009-07-29 2012-08-14 用於降低甲狀旁腺激素水平的治療劑 HK1167108A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22969509P 2009-07-29 2009-07-29
US25581609P 2009-10-28 2009-10-28
US31363510P 2010-03-12 2010-03-12
PCT/US2010/043792 WO2011014707A2 (en) 2009-07-29 2010-07-29 Therapeutic agents for reducing parathyroid hormone levels

Publications (1)

Publication Number Publication Date
HK1167108A1 true HK1167108A1 (zh) 2012-11-23

Family

ID=43527590

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12107946.6A HK1167108A1 (zh) 2009-07-29 2012-08-14 用於降低甲狀旁腺激素水平的治療劑

Country Status (30)

Country Link
US (10) US8999932B2 (zh)
EP (5) EP3808363B1 (zh)
JP (3) JP5270799B2 (zh)
KR (1) KR101781841B1 (zh)
CN (2) CN102711789B (zh)
AU (1) AU2010278897B2 (zh)
BR (1) BR112012002143B8 (zh)
CA (1) CA2769525C (zh)
CY (3) CY1118388T1 (zh)
DK (2) DK2459208T3 (zh)
ES (2) ES2607954T3 (zh)
FR (1) FR17C1009I2 (zh)
HK (1) HK1167108A1 (zh)
HR (2) HRP20161614T1 (zh)
HU (3) HUE043838T2 (zh)
IL (1) IL217749A (zh)
LT (3) LT2459208T (zh)
LU (1) LUC00008I2 (zh)
MX (1) MX2012001213A (zh)
NO (1) NO2017021I1 (zh)
NZ (1) NZ597922A (zh)
PL (2) PL3192520T3 (zh)
PT (2) PT3192520T (zh)
RU (1) RU2557654C3 (zh)
SG (2) SG178143A1 (zh)
SI (2) SI2459208T1 (zh)
SM (1) SMT201700014B (zh)
TW (1) TWI520744B (zh)
WO (1) WO2011014707A2 (zh)
ZA (1) ZA201200726B (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008067199A2 (en) * 2006-11-16 2008-06-05 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
PL3192520T3 (pl) 2009-07-29 2019-08-30 Kai Pharmaceuticals, Inc. Środki lecznicze do zmniejszania poziomów parathormonu
EP2543660A4 (en) 2010-03-04 2014-04-30 Ajinomoto Kk PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST DIABETES OR ADIPOSITAS
CN102781910B (zh) 2010-03-04 2015-03-11 味之素株式会社 烷基胺衍生物
WO2011118843A1 (ja) 2010-03-24 2011-09-29 味の素株式会社 グルタミン酸エステル誘導体又はその塩
EP2554165A4 (en) 2010-04-02 2014-04-30 Ajinomoto Kk PROPHYLACTIC OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY
BR112013031539A2 (pt) * 2011-06-08 2019-07-30 Kai Pharmaceuticals Inc agentes terapêuticos para regular fósforo sérico
AU2012335009B2 (en) * 2011-11-10 2017-08-31 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use
JP2015514771A (ja) * 2012-04-17 2015-05-21 ブラウン ユニバーシティ 神経保護性組成物および使用方法
US20200354428A9 (en) 2013-06-23 2020-11-12 Wisconsin Alumni Research Foundation Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles
CA2916222C (en) 2013-06-28 2021-05-18 Amgen Inc. Stable liquid formulation of amg 416 (etelcalcetide)
DK3126373T3 (da) * 2014-04-03 2020-05-04 Amgen Inc Fremgangsmåde til fremstilling af amg 416
CN105504012A (zh) * 2014-09-30 2016-04-20 深圳翰宇药业股份有限公司 一种多肽的制备方法
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
EP3274360B1 (en) * 2015-03-26 2020-05-06 Amgen Inc. Solution phase method for preparing etelcalcetide
US9336841B1 (en) * 2015-04-16 2016-05-10 Taiwan Semiconductor Manufacturing Co., Ltd. Pipeline register with data alignment therein
CN106928320B (zh) 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN106928321B (zh) * 2015-12-31 2019-07-26 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
WO2018044468A1 (en) * 2016-08-30 2018-03-08 Wisconsin Alumni Research Foundation COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM
US20200261549A1 (en) * 2017-11-07 2020-08-20 Alphacore Pharma Llc Methods of treating and protecting against cardiac disease, cardiovascular disease and related conditions and symptoms
WO2019124411A1 (ja) 2017-12-20 2019-06-27 Ｅａファーマ株式会社 維持透析下の二次性副甲状腺機能亢進症の予防または治療用医薬組成物
KR20210124958A (ko) * 2018-11-02 2021-10-15 앰퍼샌드 바이오파마슈티컬스, 인코포레이티드 국소적으로 적용되는 완충제(buffers)를 사용하는 양이온 과부하 및 전해질 불균형의 위험 가능성 관리를 위한 제형 및 방법
US20220142958A1 (en) 2019-04-03 2022-05-12 Ea Pharma Co., Ltd. Medicinal composition having excellent stability
KR20220110789A (ko) * 2019-12-09 2022-08-09 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 칼슘 감지 수용체 효능제 화합물 및 이의 응용
US20230223125A1 (en) * 2020-05-04 2023-07-13 University Of Louisville Research Foundation, Inc. Artificial intelligence-based systems and methods for dosing of pharmacologic agents
WO2022052471A1 (zh) * 2020-09-10 2022-03-17 陕西麦科奥特科技有限公司 双特异性融合多肽化合物
US11359134B2 (en) 2020-10-19 2022-06-14 Saudi Arabian Oil Company Treatment fluids and methods for recovering hydrocarbons from a subterranean formation
CN117500820A (zh) * 2021-06-08 2024-02-02 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用
EP4353248A1 (en) * 2021-06-08 2024-04-17 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Calcium-sensing receptor agonist composition and application thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
AU9131091A (en) 1990-11-07 1992-06-11 Scripps Research Institute, The Peptides that inhibit platelet binding of adhesion molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
CA2145214A1 (en) 1995-02-28 1996-08-29 Rick E. Preddie Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
DE69734157T2 (de) 1996-07-31 2006-07-13 The General Hospital Corp., Boston Parathyroidhormon-verwandthe peptidanaloge
US5895368A (en) 1996-09-23 1999-04-20 Medisystems Technology Corporation Blood set priming method and apparatus
WO1998017299A1 (en) 1996-10-18 1998-04-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase c, methods and compositions
WO1998033812A1 (en) 1997-02-05 1998-08-06 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
UA62967C2 (en) * 1997-05-14 2004-01-15 Aventis Pharm Prod Inc Peptide analogs of parathyroid hormons
GB2341390B (en) * 1997-05-21 2000-11-08 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
JP2000336099A (ja) 1999-05-27 2000-12-05 Sekisui Chem Co Ltd ペプチド及びｃ型肝炎抗体検出用試薬
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US20020068342A1 (en) * 2000-02-09 2002-06-06 Rami Khosravi Novel nucleic acid and amino acid sequences and novel variants of alternative splicing
JP2004504295A (ja) 2000-07-18 2004-02-12 ボーン　ケア　インターナショナル　インコーポレイテッド 安定化１α−ヒドロキシビタミンＤ
DE10041126A1 (de) * 2000-08-22 2002-04-04 Aventis Res & Tech Gmbh & Co DNA-bindende Peptiddomänen und ein Verfahren zur Bereitstellung solcher Domänen
US20080249016A1 (en) * 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US20020168354A1 (en) 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
CA2434643C (en) 2001-01-18 2013-10-29 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of.delta.pkc
US20030091640A1 (en) 2001-02-08 2003-05-15 Srinivasan Ramanathan Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents
US20030036627A1 (en) 2001-02-16 2003-02-20 Montelaro Ronald C. Virus derived antimicrobial peptides
CA2439178C (en) 2001-02-23 2013-06-04 Polyphor Ltd. Template-fixed peptidomimetics with antimicrobial activity
US6790833B2 (en) * 2001-08-08 2004-09-14 The Research Foundation Of The State University Of New York Antifungal and antibacterial agents
WO2003013543A1 (en) 2001-08-08 2003-02-20 Genomed, Llc Treatment or prevention of acute renal failure
US7060023B2 (en) 2001-09-25 2006-06-13 The Foundry Inc. Pericardium reinforcing devices and methods of using them
JP2005287302A (ja) 2002-04-03 2005-10-20 Haruhiko Fujiwara ポリペプチドの架橋方法
US20040018976A1 (en) 2002-05-14 2004-01-29 Feder John N. Polynucleotide encoding novel human G-protein coupled receptors, and splice variants thereof
ATE377023T1 (de) 2003-11-05 2007-11-15 Pevion Biotech Ltd Zusammensetzungen, die von melittin abgeleitet sind und peptide enthalten, und verfahren zur potenzierung von immunreaktionen gegen target- antigene
KR20070004571A (ko) 2003-12-11 2007-01-09 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 단백질 키나제 ｃ의 동종효소-특이적 길항제
WO2005072340A2 (en) 2004-01-27 2005-08-11 Compugen Ltd. Novel polynucleotides encoding polypeptides and methods using same
US20060052303A1 (en) * 2004-07-27 2006-03-09 Sampath Kuber T Use of thyrotropin for regeneration of bone
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
KR100687932B1 (ko) * 2005-08-09 2007-02-27 삼성전자주식회사 영상표시장치 및 영상표시방법
WO2007027510A2 (en) * 2005-08-30 2007-03-08 Acologix, Inc. Regulation of mineral and skeletal metabolism
WO2008067199A2 (en) * 2006-11-16 2008-06-05 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
KR101775929B1 (ko) 2007-01-19 2017-09-07 카이 파마슈티컬즈 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
EP2197495A2 (en) 2007-10-02 2010-06-23 MDRNA, Inc. Lipopeptides for delivery of nucleic acids
US8716437B2 (en) 2007-12-07 2014-05-06 Steven A. Goldstein Identification of toxin ligands
US20090318351A1 (en) * 2008-03-12 2009-12-24 Kevin Grimes Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist
PL3192520T3 (pl) 2009-07-29 2019-08-30 Kai Pharmaceuticals, Inc. Środki lecznicze do zmniejszania poziomów parathormonu
BR112013031539A2 (pt) 2011-06-08 2019-07-30 Kai Pharmaceuticals Inc agentes terapêuticos para regular fósforo sérico
AU2012335009B2 (en) 2011-11-10 2017-08-31 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use

Also Published As

Publication number Publication date
SMT201700014B (it) 2017-03-08
US20190194252A1 (en) 2019-06-27
LT2459208T (lt) 2017-02-27
LTC2459208I2 (lt) 2021-07-12
TWI520744B (zh) 2016-02-11
ES2607954T3 (es) 2017-04-04
PT2459208T (pt) 2017-01-03
FR17C1009I1 (zh) 2017-04-21
CN102711789B (zh) 2018-06-08
EP3808363B1 (en) 2022-09-07
HRP20190923T1 (hr) 2019-10-04
US9567370B2 (en) 2017-02-14
JP2013155195A (ja) 2013-08-15
HRP20161614T1 (hr) 2017-02-24
KR101781841B1 (ko) 2017-09-26
RU2012107428A (ru) 2013-09-10
WO2011014707A2 (en) 2011-02-03
DK2459208T3 (en) 2017-01-23
JP2013500990A (ja) 2013-01-10
RU2557654C3 (ru) 2017-07-05
NZ597922A (en) 2015-01-30
EP3192520A1 (en) 2017-07-19
EP2459208A2 (en) 2012-06-06
KR20120104513A (ko) 2012-09-21
US8377880B2 (en) 2013-02-19
CN102711789A (zh) 2012-10-03
RU2557654C2 (ru) 2015-07-27
LT3192520T (lt) 2019-06-25
MX2012001213A (es) 2012-06-12
AU2010278897B2 (en) 2015-02-26
EP4154900A1 (en) 2023-03-29
HUE043838T2 (hu) 2019-09-30
CA2769525C (en) 2017-02-21
US20180022777A1 (en) 2018-01-25
FR17C1009I2 (fr) 2019-04-12
CN107674114A (zh) 2018-02-09
AU2010278897A1 (en) 2012-02-23
SG10201406921SA (en) 2014-11-27
SI3192520T1 (sl) 2019-08-30
US8999932B2 (en) 2015-04-07
EP3539555A1 (en) 2019-09-18
EP3192520B1 (en) 2019-03-06
TW201116290A (en) 2011-05-16
BR112012002143B1 (pt) 2020-12-08
PL2459208T3 (pl) 2017-05-31
ES2729051T3 (es) 2019-10-30
DK3192520T3 (da) 2019-05-27
WO2011014707A3 (en) 2011-07-07
CN107674114B (zh) 2022-10-25
CY1118388T1 (el) 2017-06-28
EP2459208A4 (en) 2014-06-04
US20170114095A1 (en) 2017-04-27
EP3539555B1 (en) 2020-12-30
NO2017021I1 (no) 2017-05-05
US10280198B2 (en) 2019-05-07
US9701712B2 (en) 2017-07-11
JP2014094967A (ja) 2014-05-22
PL3192520T3 (pl) 2019-08-30
EP2459208B1 (en) 2016-09-28
JP5270799B2 (ja) 2013-08-21
LUC00008I1 (zh) 2017-03-16
CY2017010I2 (el) 2017-11-14
BR112012002143B8 (pt) 2021-05-25
US20130150297A1 (en) 2013-06-13
HUE030960T2 (en) 2017-06-28
IL217749A0 (en) 2012-03-29
ZA201200726B (en) 2013-05-29
US20120178688A1 (en) 2012-07-12
HUS1700008I1 (hu) 2017-04-28
BR112012002143A2 (pt) 2016-11-08
PT3192520T (pt) 2019-06-12
LTPA2017007I1 (lt) 2017-03-27
CY1121922T1 (el) 2020-10-14
US20150175664A1 (en) 2015-06-25
US20110028394A1 (en) 2011-02-03
US20200399309A1 (en) 2020-12-24
SG178143A1 (en) 2012-03-29
SI2459208T1 (sl) 2017-04-26
US20160159860A1 (en) 2016-06-09
CY2017010I1 (el) 2017-11-14
LUC00008I2 (zh) 2017-05-30
CA2769525A1 (en) 2011-02-03
JP5764613B2 (ja) 2015-08-19
EP3808363A1 (en) 2021-04-21
US9278995B2 (en) 2016-03-08
IL217749A (en) 2016-09-29
US20240116983A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
HUS1700008I1 (hu) Terápiás szerek a mellékpajzsmirigy-hormon szintjének csökkentésére
GB0908957D0 (en) Therapeutic agents
HK1182332A1 (zh) 用以改善性良好度的組合物
IL214919A0 (en) Method for therapeutic use
HK1171682A1 (zh) 鼻炎治療劑
EP2427183A4 (en) THERAPEUTIC COMPOUNDS
GB0900484D0 (en) Therapeutic agent
GB0910493D0 (en) Therapeutic agents
GB0915586D0 (en) Therapeutic agents
GB0911965D0 (en) Therapeutic agents
GB0919821D0 (en) Therapeutic agents
GB0919819D0 (en) Therapeutic agents
GB0919829D0 (en) Therapeutic agents
GB0919820D0 (en) Therapeutic agents
GB0919825D0 (en) Therapeutic agents
GB0902450D0 (en) Therapeutic agents
GB0919824D0 (en) Therapeutic agents
GB0914533D0 (en) Therapeutic agents
GB0903949D0 (en) Therapeutic agents
GB0907971D0 (en) Therapeutic agents
GB201014963D0 (en) Therapeutic agents
GB201012102D0 (en) Therapeutic agents
GB201012101D0 (en) Therapeutic agents
GB201012100D0 (en) Therapeutic agents
GB201010577D0 (en) Therapeutic agents